Literature DB >> 19751825

The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials.

Justine N Whitham1, Nicola J Spurrier, Michael G Sawyer, Peter A Baghurst, John E Taplin, Jason M White, Andrea L Gordon.   

Abstract

This study compared the neurological development of 4 month old infants exposed to buprenorphine or methadone during pregnancy to that of a control group of non-exposed infants. Participants were 30 buprenorphine-maintained women, 22 methadone-maintained women and 33 non opioid-dependent controls, and their infants. Women were enrolled during pregnancy as part of an open-label non-randomised flexible-dosing longitudinal study. Groups were matched for maternal age, parity, gravida, and tobacco and alcohol use. Infant neurological development was assessed by measuring latency of pattern reversal visual evoked potentials (VEP). One-way between groups analyses of variance (ANOVA) were conducted to test the statistical significance of differences between the mean latencies of the peak response to two different sized checkerboard patterns (48' and 69' of retinal arc). Infants prenatally exposed to methadone had significantly prolonged latencies, compared with infants in the control group and infants prenatally exposed to buprenorphine, in response to checks of 48' and 69'. VEP latencies of infants prenatally exposed to buprenorphine did not differ significantly from controls for either check size. After adjustment for covariates, prenatal exposure to methadone remained a significant predictor of VEP response to checks of 48', but not 69'. Maternal self-reported used of marijuana during pregnancy made a significant unique contribution to the variance in P1 latencies for both check sizes. Data from this controlled, non-randomised study suggest that buprenorphine may confer an advantage over methadone as a maintenance drug during pregnancy in terms of infant neural development at 4 months of age. Copyright (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19751825     DOI: 10.1016/j.ntt.2009.09.001

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  11 in total

Review 1.  Prenatal drug exposure from infancy through emerging adulthood: Results from neuroimaging.

Authors:  Kristen P Morie; Michael J Crowley; Linda C Mayes; Marc N Potenza
Journal:  Drug Alcohol Depend       Date:  2019-02-28       Impact factor: 4.492

2.  Evidence for the Normalization Effects of Medication for Opioid Use Disorder on Functional Connectivity in Neonates with Prenatal Opioid Exposure.

Authors:  Janelle Liu; Karen Grewen; Wei Gao
Journal:  J Neurosci       Date:  2022-05-12       Impact factor: 6.709

Review 3.  Buprenorphine use in pregnant opioid users: a critical review.

Authors:  Michael Soyka
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

Review 4.  Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Authors:  Hendrée E Jones; Sarah H Heil; Andjela Baewert; Amelia M Arria; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Gabriele Fischer
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

5.  Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes.

Authors:  Karol Kaltenbach; Kevin E O'Grady; Sarah H Heil; Amy L Salisbury; Mara G Coyle; Gabriele Fischer; Peter R Martin; Susan Stine; Hendrée E Jones
Journal:  Drug Alcohol Depend       Date:  2018-02-01       Impact factor: 4.492

6.  Congenital nystagmus in two infants born from mothers exposed to methadone during pregnancy.

Authors:  Francesca Tinelli; Alessandra Gamucci; Roberta Battini; Giovanni Cioni
Journal:  Ital J Pediatr       Date:  2013-07-03       Impact factor: 2.638

7.  Prenatal methadone exposure is associated with altered neonatal brain development.

Authors:  Victoria J Monnelly; Devasuda Anblagan; Alan Quigley; Manuel Blesa Cabez; E Sarah Cooper; Helen Mactier; Scott I Semple; Mark E Bastin; James P Boardman
Journal:  Neuroimage Clin       Date:  2017-12-24       Impact factor: 4.881

8.  A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes.

Authors:  Ingunn O Lund; Gabriele Fischer; Gabrielle K Welle-Strand; Kevin E O'Grady; Kimber Debelak; William R Morrone; Hendrée E Jones
Journal:  Subst Abuse       Date:  2013-03-14

Review 9.  Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis.

Authors:  Alex Baldacchino; Kathleen Arbuckle; Dennis J Petrie; Colin McCowan
Journal:  BMC Psychiatry       Date:  2014-04-08       Impact factor: 3.630

Review 10.  Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.

Authors:  Barbara K Zedler; Ashley L Mann; Mimi M Kim; Halle R Amick; Andrew R Joyce; E Lenn Murrelle; Hendrée E Jones
Journal:  Addiction       Date:  2016-06-30       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.